Werbung
Werbung

BCAX

BCAX logo

Bicara Therapeutics Inc. Common Stock

17.96
USD
Gesponsert
+1.40
+8.45%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

18.83

+0.87
+4.84%

BCAX Ergebnisberichte

Positives Überraschungsverhältnis

BCAX übertreffen die 1 der letzten 5Schätzungen.

20%

Nächster Bericht

Datum des nächsten Berichts
24. März 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.69
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
+2.99%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
+76.92%

Bicara Therapeutics Inc. Common Stock earnings per share and revenue

On 10. Nov. 2025, BCAX reported earnings of -0.67 USD per share (EPS) for Q3 25, missing the estimate of -0.56 USD, resulting in a -19.60% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of -0.69 USD, with revenue projected to reach -- USD, implying an increase of 2.99% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Bicara Therapeutics Inc. Common Stock reported EPS of -$0.67, missing estimates by -19.6%, and revenue of $0.00, 0% as expectations.
The stock price moved down -4.85%, changed from $14.64 before the earnings release to $13.93 the day after.
The next earning report is scheduled for 24. März 2026.
Based on 13 analysts, Bicara Therapeutics Inc. Common Stock is expected to report EPS of -$0.69 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung